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AKT

:   protein kinase B

ccRCC

:   clear cell renal cell carcinoma

mTOR

:   mammalian target of rapamycin

PHLPP1

:   PH domain and leucine‐rich repeat protein phosphatase 1

PI3K

:   phosphatidylinositol 3‐kinase

RCC

:   renal cell carcinoma

TCGA

:   The Cancer Genome Atlas

UAF1

:   ubiquitin‐specific peptidase 1‐associated factor 1

USP

:   ubiquitin‐specific peptidase

Renal cell carcinoma (RCC) accounts for approximately 3% of all adult malignancies and 90--95% of all kidney neoplasms.[1](#cas12892-bib-0001){ref-type="ref"} Clear cell RCC (ccRCC) is the most common histological subtype, accounting for approximately 70--80% of RCC cases.[1](#cas12892-bib-0001){ref-type="ref"}, [2](#cas12892-bib-0002){ref-type="ref"} Among the various clinicopathological features of ccRCC, nuclear grading, also known as the Fuhrman grading,[3](#cas12892-bib-0003){ref-type="ref"} is the most useful prognostic parameter. Patients with nuclear grades 3 and 4 (high‐grade) ccRCC have been reported to show a poorer survival rate than those with nuclear grades 1 and 2 (low‐grade) ccRCC.[3](#cas12892-bib-0003){ref-type="ref"}

Previously, to reveal the alterations associated with the malignant transformation of ccRCC, we analyzed the genomic alterations in 26 cases of ccRCC (11 low‐grade and 15 high‐grade). We found that 14q loss occurred more frequently in high‐grade than in low‐grade ccRCCs, and that many of the genes located on 14q were downregulated due to copy number loss.[4](#cas12892-bib-0004){ref-type="ref"} Recently, using a relatively large cohort (246 cases), Klatte *et al*.[5](#cas12892-bib-0005){ref-type="ref"} also showed that 14q loss was associated with a higher TNM stage, higher nuclear grade, larger tumor size, and poorer prognosis. It has also been reported that 14q loss is associated with poorer survival,[5](#cas12892-bib-0005){ref-type="ref"}, [6](#cas12892-bib-0006){ref-type="ref"}, [7](#cas12892-bib-0007){ref-type="ref"}, [8](#cas12892-bib-0008){ref-type="ref"} a higher Fuhrman grading[5](#cas12892-bib-0005){ref-type="ref"}, [6](#cas12892-bib-0006){ref-type="ref"} and distant metastasis.[5](#cas12892-bib-0005){ref-type="ref"} These data from our group and others[5](#cas12892-bib-0005){ref-type="ref"}, [6](#cas12892-bib-0006){ref-type="ref"}, [7](#cas12892-bib-0007){ref-type="ref"}, [8](#cas12892-bib-0008){ref-type="ref"} suggest that 14q loss is involved in the malignant transformation of ccRCC through downregulation of tumor suppressor genes located in this region. However, the mechanism by which 14q loss affects the malignant transformation of ccRCC remains largely unknown.

In the present study, to identify the gene(s) responsible for 14q loss from among those located in the minimal common region involved, 14q32.31‐33, determined in our previous study,[4](#cas12892-bib-0004){ref-type="ref"} we compared the expression of these genes between low‐ and high‐grade ccRCCs and analyzed the effect of downregulation of the candidate genes on prognosis by using the ccRCC dataset from The Cancer Genome Atlas (TCGA). Furthermore, we examined the possible tumor‐suppressive function of WDR20, whose expression was downregulated in high‐grade ccRCC due to copy number loss at14q and associated with poorer prognosis.

Materials and Methods {#cas12892-sec-0002}
=====================

Details of array data analysis, vector construction, establishment of stable cell lines, removal of integrated cDNA, isolation of cells by cell sorting, RNA extraction, quantitative RT‐PCR, invasion assay, gene expression microarray analysis, treatment of cells with 5‐aza‐2′‐deoxycytidine and trichostatin A, and migration assay are provided in Document S1.

Patients {#cas12892-sec-0003}
--------

Primary tumors of RCC were surgically resected at Oita University Hospital and Oita Red Cross Hospital (Oita, Japan) and diagnosed histopathologically as described previously[4](#cas12892-bib-0004){ref-type="ref"}, [9](#cas12892-bib-0009){ref-type="ref"} (Table S1). Use of the tissue samples for all experiments was approved by the Oita University Ethics Committee (approval no. P‐05‐05).

Dataset analysis {#cas12892-sec-0004}
----------------

Datasets pertaining to mRNA expression, DNA copy number, and clinical information for 499 ccRCC patients from the TCGA Research Network (<http://cancergenome.nih.gov/>) were analyzed using cBioPortal for Cancer Genomics (<http://www.cbioportal.org>).[10](#cas12892-bib-0010){ref-type="ref"}, [11](#cas12892-bib-0011){ref-type="ref"} The patients were considered to have high and low expression of each candidate gene based on Z scores of \>0 and \<−2, respectively. Also, the genomic copy number status of each candidate gene was determined using Affymetrix (Santa Clara, CA, USA) SNP6 array‐based GISTIC analysis, in which values of −2, −1, 0, 1, and 2 represent putative homozygous deletion, hemizygous deletion, no change, gain, and high‐level amplification, respectively.

Cell lines {#cas12892-sec-0005}
----------

The RCC cell lines 786‐O and 769‐P were purchased from ATCC (Manassas, VA, USA) and maintained in accordance with the supplier\'s instructions.

Western blot analysis {#cas12892-sec-0006}
---------------------

Western blotting was carried out as described previously with slight modifications.[12](#cas12892-bib-0012){ref-type="ref"} The primary antibodies were: anti‐FLAG M2 (Sigma‐Aldrich, St. Louis, MO, USA), anti‐p‐AKT S473 D9E, anti‐pan AKT, anti‐p‐ERK, anti‐total ERK (Cell Signaling Technology, Danvers, MA, USA), anti‐WDR20 (Bethyl, Montgomery, TX, USA), and anti‐GAPDH (Sigma‐Aldrich). Detection was carried out with ECL Prime Western Blotting Detection Reagents (Amersham Biosciences, Piscataway, NJ, USA) in accordance with the manufacturer\'s instructions. GAPDH was used as an internal control.

Proliferation assay {#cas12892-sec-0007}
-------------------

We cultured 1 × 10^3^ cells of each cell line in 96‐well plates for 0, 48, 72, and 96 h, and measured the viabilities of the cells using the CellTiter96 aqueous one solution cell proliferation assay (Promega, Madison, WI, USA) in accordance with the manufacturer\'s instructions.

Colony formation assay {#cas12892-sec-0008}
----------------------

For stably transfected cell lines, 100 cells were cultured in 10‐cm dishes for 14 days. For transiently transfected cells, 1 × 10^5^ cells were cultured in a 10‐cm dish and selected with G418 (1.2 mg/mL) for 14 days. The resulting colonies were fixed with 10% buffered formalin, stained with 0.05% toluidine blue solution (pH 7.0) (Wako, Osaka, Japan) and quantified.

Apoptosis assay {#cas12892-sec-0009}
---------------

We evaluated the induction of apoptosis by measuring cytoplasmic oligonucleosomal fragments and caspase 3/caspase 7 activities. Cytoplasmic oligonucleosomal fragments of the cells cultured for 72 h in a 96‐well plate were measured with a Cell Death Detection ELISA^PLUS^ kit (Roche Applied Science, Mannheim, Germany) in accordance with the manufacturer\'s instructions. Activities of caspase 3 and 7 in the cells cultured for 96 h in a 96‐well plate were determined using a caspase‐Glo 3/7 assay kit (Promega) in accordance with the manufacturer\'s instructions.

Statistical analysis {#cas12892-sec-0010}
--------------------

Differences in the expression levels of the candidate genes between low‐ and high‐grade ccRCCs were determined by the Wilcoxon test and Tukey--Kramer test. Associations between the expression levels of candidate genes and patient survival were expressed by Kaplan--Meier curves and analyzed by log--rank test in cBioPortal. Differences in quantitative RT‐PCR, proliferation, colony formation, invasion, migration, and apoptosis assays were analyzed by two‐sided Student\'s *t*‐test. Values are expressed as mean ± SEM. Differences at *P* values of \<0.05 were considered to be statistically significant.

Results {#cas12892-sec-0011}
=======

Genomic loss of 14q is associated with downregulation of *WDR20*,*BAG5*,*ZFYVE21*,*ZNF839*, and *C14orf79* in high‐grade ccRCCs {#cas12892-sec-0012}
-------------------------------------------------------------------------------------------------------------------------------

To identify genes located in the minimal common region of 14q loss and downregulated due to copy number loss, we compared the gene expression profiles of ccRCCs with and without 14q loss. Among the genes located on 14q32.31‐33, six showed an expression level of \<0.75 in cases with 14q loss relative to those without 14q loss (Table S2). In addition, we found that five of these six genes were significantly downregulated in high‐grade relative to low‐grade ccRCCs while the remaining gene showed no difference, suggesting that downregulation of these five genes, *WDR20*,*BAG5*,*ZFYVE21*,*ZNF839*, and *C14orf79*, may be related to malignant transformation of ccRCC (Table S2, Figs [1](#cas12892-fig-0001){ref-type="fig"}, S1).

![Significant associations between downregulation of *WDR20*,*BAG5*,*ZFYVE21*,*ZNF839*, and *C14orf79* and high grade in clear cell renal cell carcinomas. Expression levels of *WDR20* (A), *BAG5* (B), *ZFYVE21* (C), *ZNF839* (D), and *C14orf79* (E) were determined by microarray analysis and compared between normal kidney tissues (normal, *n* = 16), and low‐grade (low, *n* = 16) and high‐grade (high, *n* = 16) clear cell renal cell carcinomas. The *y*‐axis represents the expression level (log~2~) normalized by the median expression level for the 16 normal samples. Comparisons between groups were determined by Wilcoxon test and Tukey--Kramer test. \**P* \< 0.05, \*\**P* \< 0.01.](CAS-107-417-g001){#cas12892-fig-0001}

Downregulation of *WDR20* due to copy number loss is related to poorer outcome of patients with ccRCCs {#cas12892-sec-0013}
------------------------------------------------------------------------------------------------------

Next, we analyzed the associations between downregulation of each of the above five genes and patient survival using a TCGA dataset.[13](#cas12892-bib-0013){ref-type="ref"} Although downregulation of four of the five genes had no correlation with prognosis, a lower level of WDR20 expression was significantly associated with a poorer outcome (Figs [2](#cas12892-fig-0002){ref-type="fig"}A,S2). As shown in Figure [2](#cas12892-fig-0002){ref-type="fig"}(B), we also found that patients with *WDR20* gene copy number loss showed a poorer outcome than those without such loss. Furthermore, the copy number of *WDR20* was strongly correlated with the level of its mRNA (Fig. [2](#cas12892-fig-0002){ref-type="fig"}C). These results suggest that downregulation of *WDR20* due to genomic copy number loss is associated with poorer survival of patients with ccRCCs. The expression level and copy number of *WDR20* were also significantly associated with T stage, lymph node metastasis, and distant metastasis in the TCGA dataset (Table S3). A significant association between *WDR20* expression and T stage was also observed in our dataset (Fig. S3). Additionally, our dataset revealed a tendency for an association between *WDR20* expression and vascular involvement, although this did not reach statistical significance (*P* = 0.0975, Fig. S3).

![Correlation between mRNA level or copy number of *WDR20* and disease‐free survival rate in patients with clear cell renal cell carcinoma (ccRCC). Kaplan--Meier survival curves of the disease‐free survival rate in patients with ccRCCs according to the expression level (A) and copy number status (B) of *WDR20* were generated using The Cancer Genome Atlas dataset. (A) Patients with low *WDR20* expression (Z score \<−2, *n* = 131; preoperative therapy, *n* = 3) had a significantly worse survival rate than those with high *WDR20* expression (Z score \>0, *n* = 112; preoperative therapy, *n* = 3) as determined by log--rank test *(P* = 0.0112). (B) Patients with genomic copy number loss of *WDR20* from GISTIC analysis (GISTIC ≤−1, *n* = 185; preoperative therapy, *n* = 5) had a significantly worse survival rate than those without loss of *WDR20* (GISTIC ≥0, *n* = 205; preoperative therapy, *n* = 5) as determined by log--rank test *(P* = 0.002). (C) The genomic copy number of *WDR20* was significantly correlated with the expression level of *WDR20* in 394 cases of ccRCC obtained from The Cancer Genome Atlas dataset (Pearson correlation coefficient = 0.782, *P* \< 0.01)](CAS-107-417-g002){#cas12892-fig-0002}

Although almost all ccRCCs with 14q loss showed single‐copy genomic loss of *WDR20* as judged by array CGH analysis,[4](#cas12892-bib-0004){ref-type="ref"} mutational inactivation of the remaining *WDR20* allele appeared unlikely, as somatic mutation of *WDR20* was not detected at all in the TCGA dataset. However, treatment with a combination of the DNA demethylating agent 5‐aza‐dC and the histone deacetylase inhibitor trichostatin A (TSA) resulted in slight but statistically significant upregulation of *WDR20* (Fig. S4), suggesting that epigenetic modifications may be partly involved in silencing of *WDR20* on the remaining allele in ccRCC with 14q loss (Fig. S4).

Exogenous expression of WDR20 inhibits cell proliferation and induces apoptosis in RCC cells {#cas12892-sec-0014}
--------------------------------------------------------------------------------------------

To determine whether expression of *WDR20* regulates the proliferation of RCC cells, we transfected 786‐O cells, which show hemizygous loss and downregulation of *WDR20* [14](#cas12892-bib-0014){ref-type="ref"}(Fig. S5), with a plasmid encoding FLAG‐tagged *WDR20* cDNA and carried out colony formation assays. Overexpression of *WDR20* in the transfected cells was confirmed by Western blotting (Fig. [3](#cas12892-fig-0003){ref-type="fig"}Aa). As shown in Figure [3](#cas12892-fig-0003){ref-type="fig"}(Ab), exogenous *WDR20* significantly inhibited the colony‐forming ability of 786‐O. Next, we established two 786‐O cell lines, 786O_WDR20 cl1 and 786O_WDR20 cl2, stably expressing *WDR20* (Figs [3](#cas12892-fig-0003){ref-type="fig"}Ba,S6), and carried out colony formation assays. Both cell lines formed fewer colonies and showed a slower growth rate than control cells (Figs [3](#cas12892-fig-0003){ref-type="fig"}Bb,c,C). The growth‐suppressive function of WDR20 was confirmed by using another RCC cell line, 769‐P, showing hemizygous loss and downregulation of *WDR20* [14](#cas12892-bib-0014){ref-type="ref"}(Fig. S5). We established two cell lines, 769P_WDR20 cl1 and 769P\_ WDR20 cl2, stably expressing *WDR20* in 769‐P. Despite only a slight increase in the level of *WDR20* mRNA in the established cells (Fig. S7A), their growth was suppressed, as assessed by MTS assay (Fig. S7B). We noticed that significant inhibition of cell viability by *WDR20* took longer to appear in 769‐P than in 786‐O cells. This may have been due to the difference in the growth speed and level of ectopically expressed *WDR20* between the two cell lines. We also investigated the effect of *WDR20* expression on RCC cell invasiveness, motility, and apoptosis. Overexpression of *WDR20* had little effect on the invasiveness and motility of 786‐O cells (Fig. [3](#cas12892-fig-0003){ref-type="fig"}D,E), but significantly induced apoptosis as assessed by detection of cytoplasmic oligonucleosomal fragments or activated caspase 3/7 (Fig. [3](#cas12892-fig-0003){ref-type="fig"}F). Taken together, our results suggest that expression of *WDR20* inhibits the growth of RCC cells partly through induction of apoptosis.

![Ectopic expression of *WDR20* suppresses cell proliferation and induces apoptosis in renal cell carcinoma cells. (A) 786‐O cells were transiently transfected with WDR20‐pPB‐Ubc‐FLIG and subjected to Western blotting (a) and colony formation assay (b, *n* = 3). (B) 786‐O cells were stably transfected with WDR20‐pPB‐Ubc‐FLIG and subjected to Western blotting (a) and colony formation assay (b, *n* = 3). Representative images of the resulting colonies are shown in (c). (C) Viabilities of stably transfected cell lines were determined by MTS assay at 0, 48, 72, and 96 h after plating (*n* = 4). The intensity of absorbance at 492 nm at 0 h was set at 1 for each cell line. (D) Invasiveness of stably transfected cell lines was determined by Matrigel invasion assay (*n* = 4). The fluorescence intensity at 494/517 nm of empty vector‐transfected cells was set at 1. (E) Migration ability was determined using Oris Cell Migration Assay -- Collagen I‐coated 96‐well plates (*n* = 4). The migration distance of empty vector‐transfected cells was set at 1. (F) Cytoplasmic oligonucleosomal fragment (a, *n* = 4), and activities of caspases 3 and 7 (b, *n* = 4) were measured for evaluation of apoptosis. The value for empty vector‐transfected cells was set at 1. The data are expressed as mean ± SEM of quadruplicate determinations, and differences were analyzed by Student\'s *t*‐test. \**P* \< 0.05, \*\**P* \< 0.01. NS, not significant.](CAS-107-417-g003){#cas12892-fig-0003}

To confirm the growth‐suppressive and apoptosis‐inducing effect of *WDR20*, we removed cDNA of *WDR20* from its stable transfectant, 786O_WDR20 cl2, using transposase, and established a subclone, 786O_WDR20 cl2wo, in which expression of *WDR20* was substantially decreased at both the protein and mRNA levels (Fig. [4](#cas12892-fig-0004){ref-type="fig"}A). As shown in Figure [4](#cas12892-fig-0004){ref-type="fig"}(B,C), we found that the growth rate inhibition and apoptosis induction in 786O_WDR20 cl2 were reduced to almost the same levels as those in the parental 786‐O cells by removal of *WDR20* cDNA, confirming that the growth inhibition and apoptosis induction in 786O\_ WDR20 cl2 were caused by the ectopically expressed *WDR20*.

![Rescue of the proliferation ability of 786O_WDR20 cl2 by removal of *WDR20* cDNA. (A) *WDR20* cDNA was removed from 786O_WDR20 cl2 (786O_WDR20cl2wo) and subjected to Western blotting (a) and quantitative RT‐PCR (b). The *y*‐axis in (b) displays the expression level (log~2~) normalized by the mean expression level for the four vector samples. (B) The effect of *WDR20* cDNA removal on the proliferation of 786O_WDR20cl2 was determined by MTS assay at 0, 48, 72, and 96 h after plating (*n* = 4). The intensity of absorbance at 492 nm at 0 h was set at 1 for each cell line. (C) The activity of caspases 3 and 7 (a, *n* = 4) was measured at 96 h after plating for induction of apoptosis. The activity of caspases 3 and 7 in empty vector‐transfected cells was set at 1. The data are expressed as mean ± SEM of quadruplicate determinations, and differences were analyzed by Student\'s *t*‐test. \**P* \< 0.05, \*\**P* \< 0.01. NS, not significant.](CAS-107-417-g004){#cas12892-fig-0004}

Expression of *WDR20* suppresses phosphorylation levels of AKT and ERK {#cas12892-sec-0015}
----------------------------------------------------------------------

To determine the mechanism by which *WDR20* inhibits cell growth and induces apoptosis, we analyzed the effect of *WDR20* overexpression on the activities of the RAF/MEK/ERK and PI3K/AKT/MTOR pathways using Western blotting. As shown in Figure [5](#cas12892-fig-0005){ref-type="fig"}, exogenous *WDR20* suppressed the phosphorylation of both ERK and AKT, whereas removal of *WDR20* cDNA reduced this suppression to the same level as that in the parental cells, suggesting that the level of *WDR20* expression is associated with activation of both ERK and AKT. We also found that several of the genes related to the RAF/MEK/ERK and/or PI3K/AKT/MTOR pathways were differentially expressed by the ectopic expression of *WDR20* (Table S4). Therefore, we concluded that growth inhibition and apoptosis induction by *WDR20* are due, at least partly, to suppression of the ERK and AKT pathways.

![*WDR20* suppresses the phosphorylation of protein kinase B (AKT) and ERK in renal cell carcinoma cells. At 72 h after plating, the vector, 786O_WDR20 cl1, and 786O_WDR20 cl2 (A) or the vector, 786O_WDR20 cl2, and 786O_WDR20cl2wo (B) were subjected to Western blot analysis using antibodies against the phosphorylated form of AKT (Ser473), total AKT, the phosphorylated form of ERK (Thr202/Tyr204), total ERK, and GAPDH.](CAS-107-417-g005){#cas12892-fig-0005}

Discussion {#cas12892-sec-0016}
==========

To identify genes whose downregulation affects the malignant characteristics of ccRCC, we focused on the minimal common region of 14q loss, which we had defined previously as 14q32.31‐33.[4](#cas12892-bib-0004){ref-type="ref"} Among the genes located in the minimal common region, *WDR20*,*BAG5*,*ZFYVE21*,*ZNF839*, and *C14orf79* were significantly downregulated in high‐grade ccRCC due to copy number loss. Although upregulation of *BAG5* and *ZFYVE21* is reportedly associated with apoptosis resistance in prostate cancer[15](#cas12892-bib-0015){ref-type="ref"} and metastasis of colorectal carcinoma,[16](#cas12892-bib-0016){ref-type="ref"} respectively, it has not yet been determined whether downregulation of any of these genes is related to tumor malignancy. In the present study, we showed for the first time that a lower level of *WDR20* expression was significantly associated with poorer outcome in patients with ccRCC. Although we cannot exclude the possibility that the other five genes also have tumor‐suppressive roles in ccRCC, our data suggest that downregulation of *WDR20* due to 14q loss contributes to the malignant transformation of ccRCC.

In this study, we found that overexpression of *WDR20* induced growth suppression and apoptosis in ccRCC cells. WDR20 is a member of the WD (tryptophan‐aspartate) repeat family of proteins that have four to 16 WD domains, each of which possesses a conserved core sequence comprising approximately 40 amino acids flanked by a GH (glycine--histidine) dipeptide at the N‐terminus and a WD dipeptide at the C‐terminus.[17](#cas12892-bib-0017){ref-type="ref"} It has been reported that WDR20, which has five WD domains, is a component of the deubiquitinase complex and stimulates the activities of two deubiquitinating enzymes, ubiquitin‐specific peptidase (USP)12 USP46, cooperatively with USP1‐associated factor 1 (UAF1).[18](#cas12892-bib-0018){ref-type="ref"} Although there are no reports about the tumor‐suppressive role of WDR20, the involvement of USP12 and USP46 in tumorigenesis has been reported previously. USP12 is known to deubiquitinate histones H2B and H2A and induce apoptosis when overexpressed in prostate cancer cells.[19](#cas12892-bib-0019){ref-type="ref"} USP12 has also been reported to inhibit the growth of prostate cancer cells by deubiquitinating PHLPP1 that dephosphorylates and inactivates AKT.[20](#cas12892-bib-0020){ref-type="ref"}, [21](#cas12892-bib-0021){ref-type="ref"} In addition, in colon cancer, it has been reported that USP46 plays a role in inhibiting the activation of AKT through deubiquitination of PHLPP1 in coordination with WDR20 and USP1‐associated factor 1.[22](#cas12892-bib-0022){ref-type="ref"} Therefore, together with these previous reports, our data suggest that *WDR20* might exert its tumor‐suppressive function through regulation of deubiquitinating enzymes, such as USP12 and USP46. Further studies are required to clarify the mechanism whereby *WDR20* induces growth suppression and apoptosis in ccRCC cells.

In the present study, we found that overexpression of *WDR20* suppressed the phosphorylation of AKT and ERK. Aberrant activation of the PI3K/AKT/MTOR and RAF/MEK/ERK pathways is frequently observed in various types of cancer, including ccRCC, and enhances the proliferation or survival of cancer cells.[13](#cas12892-bib-0013){ref-type="ref"}, [23](#cas12892-bib-0023){ref-type="ref"}, [24](#cas12892-bib-0024){ref-type="ref"} In ccRCC, enhanced activation of the PI3K/AKT/MTOR pathway is frequently observed, and this is correlated with local invasion, regional lymph node involvement, microscopic vascular invasion, distant metastasis, and poor prognosis.[25](#cas12892-bib-0025){ref-type="ref"}, [26](#cas12892-bib-0026){ref-type="ref"} At the same time, it has been reported that a high level of phospho‐ERK is frequently observed in ccRCC and correlated with poor prognosis, tumor size, invasiveness, and clinical stage.[23](#cas12892-bib-0023){ref-type="ref"}, [27](#cas12892-bib-0027){ref-type="ref"} Interestingly, molecular targeted agents that block aberrant activation of the PI3K/AKT/MTOR and/or RAF/MEK/ERK pathways, such as MTOR and multiple receptor tyrosine kinase inhibitors, are currently used for first‐line treatment of ccRCC, suggesting that activation of these pathways is the driver of ccRCC.[28](#cas12892-bib-0028){ref-type="ref"}, [29](#cas12892-bib-0029){ref-type="ref"}, [30](#cas12892-bib-0030){ref-type="ref"} Thus, our data suggest that *WDR20* suppresses the growth of ccRCC cells, at least partly, through inhibition of these driver pathways. Further studies to clarify the mechanism whereby *WDR20* regulates the phosphorylation of AKT and ERK might provide a much better understanding of feasible therapeutic strategies for ccRCC.
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**Fig. S2.** Comparison between mRNA levels for the various genes and disease‐free survival rate in patients with clear cell renal cell carcinoma.
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**Fig. S3.** Correlation between *WDR20* expression and T stage and vascular involvement in our own dataset (Table S1).
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**Fig. S4.** Involvement of epigenetic modifications in the downregulation of *WDR20* in 786‐O cells.
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**Fig. S5.** Expression of *WDR20* in HEK293T and renal cell carcinoma cell lines.
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**Fig. S6.** Expression levels of WDR20 mRNA in the vector, 786O_WDR20 cl1 and 786O_WDR20 cl2.

###### 

Click here for additional data file.

###### 

**Fig. S7.** Stable transfection of *WDR20* in 769‐P cells.
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**Fig. S8.** Isolation of GFP‐negative cells from pCMV‐hyPBase‐transfected 786O_WDR20 cl2 cells.
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**Table S1.** Clinicopathological information of patients with clear cell renal cell carcinoma
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**Table S3.** Correlations between mRNA level or copy number of *WDR20* and pathological features of The Cancer Genome Atlas dataset
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